Sanara MedTech (SMTI) 10-Q2024 Q1 Quarterly report

Filed: 13 May 24, 4:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: absent, affirmative, amalgamation, arrangement, artificial, bankruptcy, BIASURGE, bore, broad, Canada, center, Chief, cleansing, collateral, concert, confidentiality, constantly, consummate, contact, coordinate, coordinating, coordination, covenant, CRG, cycle, declare, dissolution, divest, education, employment, empowerment, episodic, expert, extension, facilitate, family, FASB, fifty, final, Fleming, GAAP, high, hub, inaccuracy, incorporate, incorporating, insolvency, irrigation, journey, kind, launched, learning, lien, lieu, living, machine, mandatory, mechanical, medicine, mission, mix, modern, modification, monitoring, MSO, multispecialty, navigation, NPs, occurrence, OfferingSM, optimal, overarching, pathogenic, paused, person, physician, predictability, premium, prepaid, prepayment, preservative, pro, program, pronouncement, prospective, rata, reactivate, registration, regulatory, renamed, repaid, resignation, resigning, retrospective, RNs, scaling, schedule, scheduled, SCP, selected, separation, simplify, spectrum, spend, staffed, thereof, thousand, THP, type, unique, University, upfront, VBC, venture, vision, voluntary, wind, Zachary

Removed: achieving, Additionally, addressing, affiliation, aid, allocate, analyze, automated, began, behalf, biofilm, BlueIO, capability, capacity, ceased, cell, closure, compatible, contemplated, contingency, Cork, criteria, debridement, decision, decline, deductible, dictate, dissolved, Distinguishing, distributor, dividend, donor, dual, efficacy, efficiently, electronic, EMR, evidencing, exceeded, expanded, experienced, exploring, fill, filler, formation, fourth, Furneaux, gain, hemostat, Holdco, impacted, investee, Judgment, Kingdom, lead, leased, licensing, minimal, mitigation, mobile, monetary, necrotic, negatively, notification, opportunistic, organic, organized, orthopedic, oxygen, PH, powder, predominantly, preference, premarket, pressure, proportionate, prove, Pulsar, recently, recommended, reflected, representation, representative, represented, resorbable, resulted, sponsorship, submitted, synergistically, system, therapy, tracking, transitioned, typical, Ultimately, void, voting, WCS, workforce

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated SMTI transcripts

SMTI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

IN ACCORDANCE WITH 18 U.S.C. SECTION 1350,

AS ADOPTED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Sanara MedTech Inc. (the “Company”) for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald T. Nixon, in my capacity as Chief Executive Officer of the Company and not in my individual capacity, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of, and for, the periods presented in the Report.

May 13, 2024

/s/ Ronald T. Nixon
Ronald T. Nixon, Chief Executive Officer

The foregoing certification is being furnished as an exhibit to the Report pursuant to Item 601(b)(32) of Regulation S-K and Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) and, accordingly, is not being filed as part of the Report for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.